Compare Baxter International Inc (BAX) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Nutrien Ltd — how do they compare? Baxter International Inc trades at $22.28 (market cap $11.26B), while Nutrien Ltd trades at $67.48 (market cap $32.62B). The key difference: Nutrien Ltd is far larger — about 2.9× Baxter International Inc's market cap, and Nutrien Ltd pays the higher dividend (3.21%). Which is the better fit depends on your goals.
| BAX | NTR | |
|---|---|---|
Market Cap | $11.26B | $32.62B |
Sector | Health | Basic Materials |
52-Week High | $29.22 | $83.94 |
52-Week Low | $15.80 | $53.64 |
Enterprise Value | $18.93B | $45.79B |
Dividend Yield | 0.92% | 3.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Nutrien (NTR) trades at $67.60, up 3.32% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 13.77 and net income margin of 8.58%. Recent earnings beat expectations in Q1 2026, and analyst consensus is strongly positive with a $79.50 price target. The company maintains solid cash flow from operations at $4.01 billion despite recent net cash outflows.
NTR presents a compelling value opportunity with reasonable valuation metrics and strong analyst support. Key risks include volatile fertilizer prices and global agricultural demand fluctuations. The upcoming Q2 2026 earnings report with expected EPS of $2.89 represents a significant near-term catalyst for price movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
